Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Department of Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
J Infect Dis. 2022 Aug 24;226(2):287-291. doi: 10.1093/infdis/jiaa783.
In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18-50 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (n = 15); nOPV2-c2: S2/S15domV/CpG40 (n = 15)) and isolated for 28 days in a purpose-built containment facility. Using stool samples collected near days 0, 14, 21, and 28, we evaluated intestinal neutralization and immunoglobulin A responses to the nOPV2s and found that nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2-specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively.
在比利时进行的一项盲法 1 期试验（EudraCT 2017-0000908-21；NCT03430349）中，先前仅使用灭活脊髓灰质炎病毒疫苗免疫的健康成年人（年龄 18-50 岁）接受了 1 剂 2 种新型 2 型口服脊髓灰质炎病毒疫苗（nOPV2-c1：S2/cre5/S15domV/rec1/hifi3（n=15）；nOPV2-c2：S2/S15domV/CpG40（n=15）），并在专门建造的隔离设施中隔离 28 天。使用在接近第 0、14、21 和 28 天收集的粪便样本，我们评估了对 nOPV2 的肠道中和及免疫球蛋白 A 反应，发现 nOPV2-c1 和 nOPV2-c2 分别在 40.0%和 46.7%的参与者中诱导了可检测到的 2 型脊髓灰质炎病毒特异性肠道中和反应。
Zotero 插件